Adult Dosing
Pharyngitis/Tonsillitis
13 yrs: 300 mg PO bid x 5-10 days or 600 mg PO qd x 10 days
Community Acquired Pneumonia
- 13 yrs: 300 mg PO bid x 10 days
Acute exacerbation of chronic bronchitis
- 13 yrs: 300 mg PO bid x 5-10 days or 600 mg PO qd x 10 days
Acute maxillary sinusitis
- 13 yrs: 300 mg PO bid or 600 mg PO qd x 10 days
Uncomplicated Skin and Skin Structure Infections
- 13 yrs: 300 mg PO bid x 10 days
Pediatric Dosing
Acute Otitis Media
- Child 6 mo-12 yrs: 14 mg/kg/day PO div bid x 5-10 days or 14 mg/kg/day PO qd x 10 days [Max 600 mg/day]
Pharyngitis/Tonsillitis
- Child 13 yrs: 300 mg PO bid x 5-10 days or 600 mg PO qd x 10 days
- Child 6 mo-12 yrs): 14 mg/kg/day PO div bid x 5-10 days or 14 mg/kg/day PO qd x 10 days [Max: 600 mg/day]
Acute Maxillary Sinusitis
- Child 13 yrs: 300 mg PO bid or 600 mg PO qd x 10 days
- Child 6 mo-12 yrs: 14 mg/kg/day PO div qd/bid x 10 days [Max: 600 mg/day]
Uncomplicated Skin and Skin Structure Infections
- Child 13 yrs: 300 mg PO bid x 10 days
- Child 6 mo-12 yrs: 14 mg/kg/day PO div bid x 10 days [Max: 600 mg/day]
[Outline]
Renal Dose Adjustment (Based on CrCl)
- < 30 mL/min
- Adults: 300 mg/day
- Child: 7 mg/kg/day. Max: 300 mg/day
- Patients on chronic hemodialysis
- Initial: 300 mg or 7 mg/kg/dose every other day
- At end of each session: 300 mg or 7 mg/kg/dose
- Subsequent dosages: 300 mg or 7 mg/kg/dose every other day
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined
- Prior to initiating therapy determine whether the patient has had previous hypersensitivity reactions to cefdinir, cephalosporins, penicillins, or other drugs
- Cautiously administer in penicillin sensitive patients as cross sensitivity may occur
- Suspend therapy on occurrence of an allergic reaction and treat accordingly if serious acute hypersensitivity takes place
- Clostridium difficile associated diarrhea which may vary in severity from mild to fatal colitis, has been reported with use of cefdinir
- Careful clinical observation and appropriate laboratory studies should be made prior to and during therapy in patients with known or suspected renal impairment
- Use of therapy in strongly suspected bacterial infection or a prophylactic indication may increase the risk of the development of drug-resistant bacteria
- Careful observation is needed in prolonged use of therapy because prolonged use may result in the overgrowth of non-susceptible organism. Appropriate measures should be taken if superinfection occurs during therapy
- Administer cautiously in patients with hx of GI disease particularly colitis
- Reduce dosage in patients with transient or persistent renal insufficiency because high and prolonged plasma concentrations of cefdinir can result following recommended doses
Cautions: Use cautiously in
Pregnancy Category:B
Breastfeeding: No information is available on the use of cefdinir during breastfeeding. However cephalosporins are compatible and considered safe with breastfeeding based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 31 December 2010).
Pricing data from www.DrugStore.com in U.S.A.
- Omnicef 250 MG/5ML SUSR [Bottle] (ABBOTT)
100 5ml = $179.99
300 5ml = $509.98 - Omnicef 125 MG/5ML SUSR [Bottle] (ABBOTT)
100 5ml = $95.43
300 5ml = $273.32 - Cefdinir 300 MG CAPS [Bottle] (LUPIN PHARMACEUTICALS)
20 mg = $55.99
60 mg = $135.96 - Cefdinir 125 MG/5ML SUSR [Bottle] (TEVA PHARMACEUTICALS USA)
60 5ml = $47.99
120 5ml = $85.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
